Skip to content

Dr. Gearóid Tuohy

New CRISPR/Cas9 gene editing tool indicates a 35% visual acuity improvement in model of autosomal dominant retinitis pigmentosa

Research conducted at the Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, has shown that CRISPR/Cas9 gene editing technology may be capable of correcting dominant… Read More »New CRISPR/Cas9 gene editing tool indicates a 35% visual acuity improvement in model of autosomal dominant retinitis pigmentosa

Ocata Therapeutics Inc., announces publication of data on the generation of corneal endothelial cells from human pluripotent stem cells

Ocata Therapeutics Inc. (NASDAQ:OCAT), based in Marlborough, Massachusetts, formerly known as Advanced Cell Technology Inc., or ACT, have announced the publication of data in the… Read More »Ocata Therapeutics Inc., announces publication of data on the generation of corneal endothelial cells from human pluripotent stem cells

Research suggests that the impact of individualized patient assessment and diabetes-risk education on glycemic control may not be sufficiently effective

Research, conducted across 42 ophthalmology centres in the United States, has reported that point-of-care measurement of hemoglobin A1c (HbA1c), combined with personalized diabetes risk assessment… Read More »Research suggests that the impact of individualized patient assessment and diabetes-risk education on glycemic control may not be sufficiently effective

Spark Therapeutics announces plans to have 10 gene therapy clinical programs in place by 2018, including up to three ophthalmic indications

Spark Therapeutics (NASDAQ:ONCE), a gene therapy company based in Philadelphia, USA, has announced a three year vision to expand the company’s gene therapy portfolio and… Read More »Spark Therapeutics announces plans to have 10 gene therapy clinical programs in place by 2018, including up to three ophthalmic indications